The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin

被引:26
作者
Lin, JC
Ito, MK
Stolley, SN
Morreale, AP
Marcus, DB
机构
[1] VA San Diego Healthcare Syst, Cardiovasc Pharmacodynam Lab, San Diego, CA 92161 USA
[2] Univ Pacific, Sch Pharm, Stockton, CA 95211 USA
关键词
D O I
10.1177/00912709922007598
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Forty-six adult patients maintained on warfarin therapy were converted from pravastatin to simvastatin. Mean international normalized ratio (INR) significantly increased from 2.42 to 2.74, p = 0.002. Although warfarin doses were reduced in 7 patients and increased in 4 patients following the post-conversion INR measurements, the pre- and postconversion median weekly warfarin dose of all 46 patients did not differ significantly. The number of patients with an INR > 3.0 increased significantly from 6 to 16 following the conversion. There was no report of unusual episodes of bleeding. The results indicate that antihyperlipidemic therapy can be changed safely from pravastatin to simvastatin in patients who are taking warfarin concomitantly;Additional anticoagulation monitoring is not necessary in institutions where patients are followed in formal anticoagulation clinics. Journal of Clinical Pharmacology; 1999;39:86-90 (C) 1999 the American College of Clinical Pharmacology.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 27 条
[1]   LOVASTATIN - WARFARIN INTERACTION [J].
AHMAD, S .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (11) :2407-2407
[2]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[3]  
Boberg M, 1997, DRUG METAB DISPOS, V25, P321
[4]   EFFECTS OF HMG COA REDUCTASE INHIBITORS ON WARFARIN-BINDING [J].
FEELY, J ;
OCONNOR, P .
DRUG INVESTIGATION, 1991, 3 (05) :315-316
[5]   SIMVASTATIN DURING WARFARIN THERAPY IN HYPERLIPOPROTEINEMIA [J].
GAW, A ;
WOSORNU, D .
LANCET, 1992, 340 (8825) :979-980
[6]   PHARMACOKINETICS OF THE ENANTIOMERS OF ACENOCOUMAROL IN MAN [J].
GODBILLON, J ;
RICHARD, J ;
GERARDIN, A ;
MEINERTZ, T ;
KASPER, W ;
JAHNCHEN, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (05) :621-629
[7]   Simvastatin-oral anticoagulant interaction [J].
Grau, E ;
Perella, M ;
Pastor, E .
LANCET, 1996, 347 (8998) :405-406
[8]   Clinically important drug interactions with anticoagulants - An update [J].
Harder, S ;
Thurmann, P .
CLINICAL PHARMACOKINETICS, 1996, 30 (06) :416-444
[9]   HUMAN LIVER MICROSOMAL METABOLISM OF THE ENANTIOMERS OF WARFARIN AND ACENOCOUMAROL - P450 ISOZYME DIVERSITY DETERMINES THE DIFFERENCES IN THEIR PHARMACOKINETICS [J].
HERMANS, JJR ;
THIJSSEN, HHW .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (01) :482-490
[10]   MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE [J].
HIRSH, J ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L ;
BUSSEY, H .
CHEST, 1995, 108 (04) :S231-S246